

AGENDA

- | | |
|-------|---|
| 14.00 | Welcome and opening remarks
Michael Engsig, Chief Executive Officer |
| 14.10 | VB10.16 program update: where we have come from, new learnings, and future plans
Klaus Edvardsen, Chief Development Officer |
| 14.30 | VB10.NEO program update (in partnership with Roche / Genentech), including longer-term follow-up data from Phase 1/2
Klaus Edvardsen, Chief Development Officer |
| 14.50 | Q&A Session |
| 15.10 | Break |
| 15.30 | Research and Innovation update: unlocking the power of the Nykode platform in oncology and autoimmunity
Mikkel Wandahl Pedersen, Chief Scientific Officer |
| 15.50 | The Nykode Business Model
Agnete B. Fredriksen, Chief Business Officer and Co-founder |
| 16.00 | Final remarks
Michael Engsig, Chief Executive Officer |
| 16.10 | Q&A Session |
| 16.30 | Reception & Networking |